
CLAIMS

1. An antisense oligomer of Compound 2:



Compound 2

wherein:

each Nu is a nucleobase which taken together form a targeting sequence; and wherein each Nu from 1 to 22 and 5' to 3' is:

Position No. 5' to 3'	Nu	Position No. 5' to 3'	Nu	Position No. 5' to 3'	Nu	Position No. 5' to 3'	Nu	Position No. 5' to 3'	Nu
1	C	6	C	11	C	16	G	21	T
2	A	7	C	12	T	17	T	22	G
3	A	8	A	13	G	18	T		
4	T	9	T	14	G	19	C		
5	G	10	C	15	A	20	C		

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising the antisense oligomer of claim 1 and a pharmaceutically acceptable carrier.

3. The antisense oligomer of claim 1 for use in the treatment of Duchenne muscular dystrophy (DMD).

4. Use of the antisense oligomer of claim 1 in the manufacture of a medicament for the treatment of Duchenne muscular dystrophy (DMD) or production of dystrophin in a subject in need thereof, wherein the subject has a mutation of the dystrophin gene that is amenable to exon 45 skipping.

5